Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Timeline
  • Published:

Ebola virus: from discovery to vaccine

Nature Reviews Immunology volume 3, pages 677–685 (2003) Cite this article

Save article
View saved research

Abstract

Ebola virus, being highly pathogenic for humans and non-human primates and the subject of former weapons programmes, is now one of the most feared pathogens worldwide. In addition, the lack of pre- and post-exposure interventions makes the development of rapid diagnostics, new antiviral agents and protective vaccines a priority for many nations. Further insight into the ecology, immunology and pathogenesis of Ebola virus will promote the delivery of these urgently required tools.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Geographical locations of Ebola-virus outbreaks.
Figure 2: Filovirus particles.
Figure 3: Pathogenesis model.

References

  1. World Health Organization. Ebola haemorrhagic fever in Sudan, 1976. Bull. WHO 56, 247–270 (1978).

  2. Pattyn, S. R. in Ebola Virus Haemorrhagic Fever 1st edn 1–436 (Elsevier, Amsterdam, Holland, 1978).

    Google Scholar 

  3. World Health Organization. Ebola haemorrhagic fever in Zaire, 1976. Bull. WHO 56, 271–293 (1978).

  4. Siegert, R. et al. Zur Äthiologie einer unbekannten von affen ausgegangenen infektionskrankheit. Dtsch. Med. Wochenschr. 92, 2341–2343 (1967).

    CAS  PubMed  Google Scholar 

  5. Jahrling, P. B. et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335, 502–505 (1990).

    CAS  PubMed  Google Scholar 

  6. LeGuenno, B. et al. Isolation and partial characterization of a new strain of Ebola virus. Lancet 345, 1271–1274 (1995).

    CAS  Google Scholar 

  7. Walsh, P. D. et al. Catastrophic ape decline in western equatorial Africa. Nature 422, 611–614 (2003).

    CAS  PubMed  Google Scholar 

  8. Borio, L. T. et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287, 2391–2405 (2002).

    PubMed  Google Scholar 

  9. Volchkov, V. E. et al. Recovery of infectious Ebola virus from cDNA: transcriptional RNA editing of the glycoprotein gene controls viral cytotoxicity. Science 291, 1965–1969 (2001).

    CAS  PubMed  Google Scholar 

  10. Neumann, G. et al. Reverse genetics demonstrates that proteolytic cleavage of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 76, 406–410 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Mühlberger, E. et al. Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes. J. Virol. 72, 8756–8764 (1998).

    PubMed  PubMed Central  Google Scholar 

  12. Mühlberger, E. et al. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 2333–2342 (1999).

    PubMed  PubMed Central  Google Scholar 

  13. Yang, Z. et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nature Med. 6, 886–889 (2000).

    CAS  PubMed  Google Scholar 

  14. Volchkov, V. E. et al. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl Acad. Sci. USA 95, 5762–5767 (1998).

    CAS  PubMed  Google Scholar 

  15. Schnittler, H. J. & Feldmann, H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr. Top. Microbiol. Immunol. 235, 175–204 (1999).

    CAS  PubMed  Google Scholar 

  16. Baskerville, A. et al. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J. Pathol. 147, 199–209 (1985).

    CAS  PubMed  Google Scholar 

  17. Geisbert, T. W. et al. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J. Comp. Path. 106, 137–152 (1992).

    CAS  PubMed  Google Scholar 

  18. Geisbert, T. W. et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80, 171–186 (2000).

    CAS  PubMed  Google Scholar 

  19. Feldmann, H. et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70, 2208–2214 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Ryabchikova, E., Kolesnikova, L. V. & Luchko, S. V. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179, S199–S202 (1999).

    PubMed  Google Scholar 

  21. Ströher, U. et al. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75, 11025–11033 (2001).

    PubMed  PubMed Central  Google Scholar 

  22. Baize, S. et al. Defective humoral response and extensive intravascular apoptosis are associated with fatal outcome of Ebola virus-infected patients. Nature Med. 5, 423–426 (1999).

    CAS  PubMed  Google Scholar 

  23. Villinger, F. et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J. Infect. Dis. 179, S188–S191 (1999).

    CAS  PubMed  Google Scholar 

  24. Leroy, E. M. et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355, 2210–2215 (2000).

    CAS  PubMed  Google Scholar 

  25. Baize, S. et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128, 163–168 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Harcourt, B. H., Sanchez, A. & Offermann, M. K. Ebola virus selectively inhibits responses to interferon, but not to interleukin-1β, in endothelial cells. J. Virol. 73, 3491–3496 (1999).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Basler, C. F. et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl Acad. Sci. USA 97, 12289–12294 (2000).

    CAS  PubMed  Google Scholar 

  28. Bray, M. et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651–661 (1998).

    CAS  PubMed  Google Scholar 

  29. Bray, M. The role of the type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 1365–1373 (2001).

    CAS  PubMed  Google Scholar 

  30. Mahanty, S. et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170, 2797–2801 (2003).

    CAS  PubMed  Google Scholar 

  31. Yang, Z. et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279, 1034–1036 (1998).

    CAS  PubMed  Google Scholar 

  32. Kindzelskii, A. L. et al. Ebola virus secretory glycoprotein (sGP) diminishes FcγRIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164, 953–958 (2000).

    CAS  PubMed  Google Scholar 

  33. Maruyama, T. et al. Ebola virus, neutrophils and antibody specificity. Science 282, 845 (1998).

    Google Scholar 

  34. Sanchez, A. et al. The virion glycoprotein of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl Acad. Sci. USA 93, 3602–3607 (1996).

    CAS  PubMed  Google Scholar 

  35. Volchkov, V. E. et al. Release of viral glycoproteins during Ebola virus infection. Virology 245, 110–119 (1998).

    CAS  PubMed  Google Scholar 

  36. Feldmann, H. et al. Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol. 82, 2839–2848 (2001).

    CAS  PubMed  Google Scholar 

  37. Volchkov, V. E., Blinov, V. M. & Netesov, S. V. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett. 305, 181–184 (1992).

    CAS  PubMed  Google Scholar 

  38. Ignatyev, G. M. Immune response to filovirus infections. Curr. Top. Microbiol. Immunol. 235, 205–217 (1999).

    CAS  PubMed  Google Scholar 

  39. Chan, S. Y., Ma, M. C. & Goldsmith, M. A. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Gen. Virol. 81, 2155–2159 (2000).

    CAS  PubMed  Google Scholar 

  40. Takada, A. et al. Downregulation of β1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278, 20–26 (2000).

    CAS  PubMed  Google Scholar 

  41. Gupta, M. et al. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75, 4649–4654 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Wong, R. K., Baldwin, A. L. & Heimark, R. L. Cadherin-5 redistribution at sites of TNF-α and IFN-γ-induced permeability in mesenteric venules. Am. J. Physiol. 276, H736–H748 (1999).

    CAS  PubMed  Google Scholar 

  43. Volchkov, V. E. et al. Molecular characterization of guinea-pig-adapted variants of Ebola virus. Virology 277, 147–155 (2000).

    CAS  PubMed  Google Scholar 

  44. Chen, J. P. & Cosgriff, T. M. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul. Fibrinolysis 11, 461–483 (2000).

    CAS  PubMed  Google Scholar 

  45. Fisher-Hoch, S. P. et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J. Infect. Dis. 152, 887–894 (1985).

    CAS  PubMed  Google Scholar 

  46. Ksiazek, T. G. et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179, S177–S187 (1999).

    PubMed  Google Scholar 

  47. Maruyama, T. et al. Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. 179, S235–S239 (1999).

    CAS  PubMed  Google Scholar 

  48. Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664–1666 (2000).

    CAS  PubMed  Google Scholar 

  49. Parren, P. W. et al. Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76, 6408–6412 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Ktysnayanskii, V. P. et al. Preparation of hyperimmune horse serum to Ebola virus. Vopr. Virusol. 39, 91–92 (1994).

    Google Scholar 

  51. Mikhailov, V. V. et al. The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Vopr. Virusol. 39, 82–84 (1994).

    CAS  PubMed  Google Scholar 

  52. Jahrling, J. B. et al. Passive immunization of Ebola virus-infected cynomologus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. 11, 135–140 (1996).

    CAS  Google Scholar 

  53. Fernandes, I., Takehara, H. A. & Mota, I. Isolation of IgGT from hyperimmune horse anti-snake venom serum: its protective ability. Toxicon. 29, 1373–1379 (1991).

    CAS  PubMed  Google Scholar 

  54. Sjostrom, L. et al. A comparison of ovine and equine antivenoms. Toxicon. 32, 427–433 (1994).

    CAS  PubMed  Google Scholar 

  55. Mupapa, K. D. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179, S18–S23 (1999).

    PubMed  Google Scholar 

  56. Takada, A. et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77, 1069–1074 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Takada, A. et al. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 75, 2324–2330 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Geisbert, T. W. et al. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology 293, 15–19 (2002).

    CAS  PubMed  Google Scholar 

  59. Takada, A. et al. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77, 7539–7544 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Ellis, D. S. et al. Ebola virus: a comparison, at ultrastructural level, of the behaviour of the Sudan and Zaire strains in monkeys. Br. J. Exp. Pathol. 59, 584–593 (1978).

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Davis, K. J. et al. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch. Pathol. Lab. Med. 121, 805–819 (1997).

    CAS  PubMed  Google Scholar 

  62. Fisher-Hoch, S. P. & McCormick, J. B. Experimental filovirus infections. Curr. Top. Microbiol. Immunol. 235, 117–143 (1999).

    CAS  PubMed  Google Scholar 

  63. Ryabchikova, E. I., Kolesnikova, L. V. & Netesov, S. V. Animal pathology of filoviral infections. Curr. Top. Microbiol. Immunol. 235, 145–173 (1999).

    CAS  PubMed  Google Scholar 

  64. Zaki, S. R. & Goldsmith, C. S. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 235, 97–116 (1999).

    CAS  PubMed  Google Scholar 

  65. Bowen, E. T. et al. Ebola haemorrhagic fever: experimental infection of monkeys. Trans. R. Soc. Trop. Med. Hyg. 72, 188–191 (1978).

    CAS  PubMed  Google Scholar 

  66. Connolly, B. M. et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179, S203–S217 (1999).

    PubMed  Google Scholar 

  67. Bray, M. et al. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J. Comp. Pathol. 125, 243–253 (2001).

    CAS  PubMed  Google Scholar 

  68. Gibb, T. R. et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125, 233–242 (2001).

    CAS  PubMed  Google Scholar 

  69. Hart, M. K. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33, 583–595 (2003).

    CAS  PubMed  Google Scholar 

  70. Lupton, H. W. et al. Inactivated vaccine for Ebola virus efficacious in guinea pig model. Lancet 2, 1294–1295 (1980).

    CAS  PubMed  Google Scholar 

  71. Mikhailov, V. V. et al. An evaluation of the possibility of Ebola fever specific prophylaxis in baboons (Papio hamadryas). Vopr. Virusol. 39, 82–84 (1994).

    CAS  PubMed  Google Scholar 

  72. Chepurnov, A. A. et al. Attempts to develop a vaccine against Ebola fever. Vopr. Virusol. 40, 257–260 (1995).

    Google Scholar 

  73. Vanderzanden, L. et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246, 134–144 (1998).

    CAS  PubMed  Google Scholar 

  74. Xu, L. et al. Immunization for Ebola virus infection. Nature Med. 4, 37–42 (1998).

    CAS  PubMed  Google Scholar 

  75. Pushko, P. et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19, 142–153 (2000).

    CAS  PubMed  Google Scholar 

  76. Sullivan, N. J. et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605–609 (2000).

    CAS  PubMed  Google Scholar 

  77. Wilson, J. A. et al. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286, 384–390 (2001).

    CAS  PubMed  Google Scholar 

  78. Geisbert, T. W. et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8, 503–507 (2002).

    PubMed  PubMed Central  Google Scholar 

  79. Gilligan, K. J. et al. in Vaccines 97 (eds Brown, F. et al.) 87–92 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1997).

    Google Scholar 

  80. Chepurnov, A. A. et al. Immunological properties of VP24 protein of Ebola virus expressed by recombinant vaccinia virus. Vopr. Virusol. 42, 115–120 (1997).

    CAS  PubMed  Google Scholar 

  81. Hevey, M. et al. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251, 28–37 (1998).

    CAS  PubMed  Google Scholar 

  82. Noda, T. et al. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76, 4855–4865 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Wool-Levis, R. J. & Bates, P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72, 3155–3160 (1998).

    Google Scholar 

  84. Becker, S., Spiess, M. & Klenk, H. D. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J. Gen. Virol. 76, 393–399 (1995).

    CAS  PubMed  Google Scholar 

  85. Chan, S. Y. et al. Folate receptor-α is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106, 117–126 (2001).

    CAS  PubMed  Google Scholar 

  86. Alvarez, C. P. et al. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76, 6841–6844 (2002).

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Martini, G. A. & Siegert, R. in Marburg Virus Disease 1st edn 1–230 (Springer, New York, 1971).

    Google Scholar 

  88. Klenk, H. D. Marburg and Ebola viruses. Curr. Top. Microbiol. Immunol. 235, 1–230 (1999).

    Google Scholar 

  89. Peters, C. J. & LeDuc, J. W. An introduction to Ebola: the virus and the disease. J. Infect. Dis. 179, 9–16 (1999).

    Google Scholar 

  90. Sanchez, A. et al. in Fields Virology 4th edn (eds Knipe, D. M. et al.) 1279–1304 (Lippincott-Williams & Wilkins, Philadelphia, Pennsylvania, 2001).

    Google Scholar 

  91. Feldmann, H. et al. Marburg and Ebola viruses: past advances and future needs. Nova Acta Leopoldina 313, 163–178 (1999).

    Google Scholar 

  92. Schnittler, H. J. & Feldmann, H. Viral hemorrhagic fever — a vascular disease? Thromb. Haemost. 89, 967–972 (2003).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank many colleagues in the field for their helpful discussions and suggestions. In particular, we thank D. Dick and A. Lacquement for critical review of the manuscript. Our work on filoviruses was supported by grants from the Deutsche Forschungsgemeinschaft (DFG), the Canadian Institutes of Health Research (CIHR), the Kempkes-Stiftung, the European Community and Health Canada.

Author information

Authors and Affiliations

  1. the National Microbiology Laboratory and Department of Medical Microbiology, Special Pathogens Program, University of Manitoba, Winnipeg, Canada

    Heinz Feldmann

  2. the National Microbiology Laboratory and Department of Immunology, Special Pathogens Program, University of Manitoba, Winnipeg, Canada

    Steven Jones

  3. the Institute for Virology, Philipps-University of Marburg, Germany

    Hans-Dieter Klenk

  4. the Institute for Physiology, Medical Faculty Carl-Gustav Carus, Technical University of Dresden, Germany

    Hans-Joachim Schnittler

Authors
  1. Heinz Feldmann
    View author publications

    Search author on:PubMed Google Scholar

  2. Steven Jones
    View author publications

    Search author on:PubMed Google Scholar

  3. Hans-Dieter Klenk
    View author publications

    Search author on:PubMed Google Scholar

  4. Hans-Joachim Schnittler
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Heinz Feldmann.

Related links

Related links

DATABASES

LocusLink

IFN-γ

IL-1β

IL-6

IL-10

IL-1RA

TNF

FURTHER INFORMATION

The international committee on taxonomy of viruses

Selected agent programme

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldmann, H., Jones, S., Klenk, HD. et al. Ebola virus: from discovery to vaccine. Nat Rev Immunol 3, 677–685 (2003). https://doi.org/10.1038/nri1154

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nri1154

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing